Mylan Ondansetron 4 mg/2 ml, 8 mg/4 ml Injection
PDF Leaflet Revision Date: 13 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Management of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative.
Dosage (summary)
Adults: 8 mg IV/IM before treatment; may follow with oral ondansetron 8 mg every 12 hours.
Special Populations
- Elderly patients
- Children over 4 years
- Patients with hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in first 12 weeks of pregnancy and during lactation.
Key Drug Interactions
- Apomorphine
- QT prolonging medications
- Serotonergic medicines
Contraindications
- Hypersensitivity to ondansetron
- Congenital long QT syndrome
- Severe hepatic impairment
Common side effects
- Headache
- Dizziness
- Constipation
Counselling Points
- Monitor for signs of QT prolongation.
- Avoid use in early pregnancy.
- Do not breastfeed while on treatment.
Serious warnings
- QT prolongation risk
- Caution in patients with cardiac history
Important Disclaimer
The Mylan Ondansetron 4 mg/2 ml, 8 mg/4 ml Injection professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
